Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;34(1):e14498.
doi: 10.1111/dth.14498. Epub 2020 Nov 10.

Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review

Ali Sadeghinia  1 , Maryam Daneshpazhooh  1
Affiliations
Review

Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review

Ali Sadeghinia et al. Dermatol Ther. 2021 Jan.

Abstract

The COVID-19 has been spreading around the world. Concerns about the safety of administration of immunosuppressive drugs have been raised for treatment of psoriasis (PSO), and there is insufficient evidence for the risk of COVID-19 infection for psoriatic patients using these drugs, so we did a review, focusing on the risk of overall infection associated with the most commonly used immunosuppressive drugs, such as methotrexate, biologics, cyclosporin, Janus kinase inhibitors for the treatment of PSO. The data on the effect of immunosuppressive drugs on this virus may be ever-changing and remains to be clear. We recommend the initiation and continuation of low-risk immunomodulating drugs, such as Interleukin (IL)-17, IL-12/23, and IL-23 inhibitors, for treatment of PSO during COVID-19 era. For psoriatic patients with comorbidities switching to safer modalities such as systemic retinoids, apremilast, and home phototherapy is recommended. Immunosuppressive drugs should be withheld in psoriatic patients with the COVID-19 infection.

Keywords: COVID-19; IL12/23 inhibitors; IL17-inhibitors; JAK inhibitors; TNFα inhibitors; cyclosporine; immunosuppressive drugs; methotrexate; psoriasis; review; risk of infection.

PubMed Disclaimer

References

REFERENCE

    1. Brownstone ND, Thibodeaux QG, Reddy VD, et al. Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: infection risk and patient counseling in uncertain times. Dermatol Ther. 2020;10(3):1-11. https://doi.org/10.1007/s13555-020-00377-9.
    1. Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther. 2020;e13687. https://doi.org/10.1111/dth.13687.
    1. Wakkee M, de Vries E, van den Haak P, Nijsten T. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol. 2011;65(6):1135-1144.
    1. Hsu DY, Gordon K, Silverberg JI. Serious infections in hospitalized patients with psoriasis in the United States. J Am Acad Dermatol. 2016;75(2):287-296.
    1. Takeshita J, Shin DB, Ogdie A, Gelfand JM. Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom. J Invest Dermatol. 2018;138(8):1726-1735.

Substances

LinkOut - more resources